Semaglutide Weight Management and Cardiovascular Risk Reduction
Semaglutide 2.4 mg demonstrated superior reduction on the
other primary endpoint of body weight vs placebo
Clinically relevant and sustained weight loss in patients treated with
semaglutide 2.4 mg
Mean baseline body weight: 108.4 kg
Change in body weight (%)
-15
-10
J
Primary endpoint:
-2.6
-13.3
•
-20
0 4 8 12
16 20
28
36
44
52 52*
Time since randomisation (weeks)
Placebo
Key highlights
Estimated treatment difference in body weight
change between semaglutide 2.4 mg and placebo of
-10.7%
Safety:
Overall, the safety profile in HFPEF patients is
consistent with previous data for semaglutide 2.4 mg
Semaglutide 2.4mg
Note: Data shown is the treatment policy estimand. *Lines are based on observed data where the value denoted after 52 weeks is estimated mean value derived based on multiple imputation
HF: Heart failureView entire presentation